Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ: ATAI )

2.300 +0.030 (+1.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ATAI Life Sciences N.V. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Psychedelic Stock Gainers And Losers From April 11, 2023
Via Benzinga
Psyched: MDMA Therapy Advances With FDA, Alternatives For Alcohol Addiction, Prince Harry In The Spotlight And More
MDMA Therapy For PTSD Nearing Legalization In U.S. And Worldwide, MAPS Releases Promising Data 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 10, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 7, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 6, 2023
Via Benzinga
Compass Pathways, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Why Atai Life Sciences Stock Stormed Higher This Week
The biotech's strong financial position may be attracting bargain buyers right now. 
Via The Motley Fool
Expert Ratings for ATAI Life Sciences
Via Benzinga
ATAI Life Sciences Earnings Perspective: Return On Capital Employed
Via Benzinga
"Rags-To-Riches" Portfolio Down 8.6% In March; Now -3.9% YTD
The 
Via Talk Markets
Psychedelic Stock Gainers And Losers From April 4, 2023
Via Benzinga
Butterfly Network, APE Preferred Shares And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
Largest Psychedelic Stocks -3.4% In March
The munKNEE Psychedelic Drug Stocks Index was down 3.4% in March but is still +1.2% YTD. The best news is the continuing high price targets being set by analysts. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From March 31, 2023
Via Benzinga
Why Shares of Atai Life Sciences Rose Friday
The company's co-founder and chairman increased his position and explained why. 
Via The Motley Fool
Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
IntelGenx's Q4 And Full-Year 2022 Financials, 'On The Cusp' Of Rapid Growth?
Drug delivery company IntelGenx Technologies Corp. (OTCQB: IGXT)’s financial results for the three and twelve months ended December 31, 2022 show: 
Via Benzinga
$1.6M Bet On ATAI Life Sciences? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed higher by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Why This Investor Is Buying More Than A Million Dollars Of A Biotech Company
Christian Angermayer, the founder and Chairman of the Board of Apeiron Investment Group, is adding more than $1,000,000 in shares of ATAI Life Sciences NV (NASDAQ: ATAI). 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 29, 2023
Via Benzinga
Why Kodiak Sciences Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers LogicMark, Inc. (NASDAQ: LGMK) shares jumped 76.1% to $0.2466 after the company announced financial results for the year ended 2022. The company reported FY22 revenue of $11.9 million. 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 28, 2023
Via Benzinga
Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 27, 2023
Via Benzinga
GH Research, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
Atai Life Sciences Hopes Hercules Can Help 'Sustain' Operations Until 2026
Biopharma company Atai Life Sciences' (NASDAQ: ATAI) fourth quarter and full year 2022 consolidated financial results show: 
Via Benzinga
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
From atai Life Sciences
Via GlobeNewswire
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From March 22, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.